cardiovascular-agents has been researched along with Chronic-Kidney-Disease-Mineral-and-Bone-Disorder* in 2 studies
2 review(s) available for cardiovascular-agents and Chronic-Kidney-Disease-Mineral-and-Bone-Disorder
Article | Year |
---|---|
Pathophysiology and treatment of cardiovascular disease in pediatric chronic kidney disease.
Life expectancy in patients with all stages of chronic kidney disease (CKD) falls far short of that in the general population. Cardiovascular disease is the leading cause of mortality in pediatric patients with CKD. In contrast to the intimal atherosclerotic lesions that characterize cardiovascular disease in the general population, vascular endothelial dysfunction, medial arterial calcification, and cardiac dysfunction contribute to cardiovascular pathological conditions in CKD. The pathogenesis of these lesions, the origins of which can be identified in the absence of traditional cardiovascular risk factors, is incompletely understood. CKD-mediated vascular calcification in CKD is characterized by a transition of vascular smooth muscle cells to an osteoblast-like phenotype and altered bone and mineral metabolism are strongly linked to progressive cardiovascular disease in this population. Renal osteodystrophy therapies, including phosphate binders, vitamin D analogs, and calcimimetics, have an impact on the progression of cardiovascular disease. However, cardiovascular disease has its origins before the development of secondary hyperparathyroidism, and optimal therapeutic regimens that minimize cardiac dysfunction, vascular calcification, and early mortality remain to be defined. Topics: Age Factors; Arteries; Bone and Bones; Calcimimetic Agents; Cardiovascular Agents; Cardiovascular Diseases; Chelating Agents; Child; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Progression; Endothelium, Vascular; Humans; Kidney Transplantation; Minerals; Renal Insufficiency, Chronic; Tunica Media; Vascular Calcification; Vitamin D | 2019 |
[Structural changes and vascular calcifications in uremia].
Topics: Antihypertensive Agents; Arterioles; Arteriosclerosis; Basement Membrane; Bone Remodeling; Calcinosis; Calcium; Cardiovascular Agents; Cardiovascular Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Diagnostic Tests, Routine; Disease Progression; Humans; Hyperparathyroidism; Hypertension; Hypertrophy, Left Ventricular; Kidney Transplantation; Osteoblasts; Renal Dialysis; Uremia; Vascular Diseases; Venules; Vitamin D | 2001 |